Veeva Unifies Submission Content Planning and Authoring to Streamline Submission Development

Number of Veeva Vault RIM customers doubles, as Veeva drives the
industry’s transition to unified RIM

CHICAGO--(BUSINESS WIRE)--DIA 2017 Annual Meeting — Veeva
Systems
(NYSE:VEEV) today introduced a new submission content
planning capability in Veeva
Vault Submissions
. For the first time, life sciences companies can
create content plans, author documents, and track status in a single
system to reduce the burden of submission development and gain greater
visibility across the end-to-end process.

Veeva innovation is enabling an industrywide move toward unified RIM.
More companies, including five of the top 20 largest global
pharmaceutical companies, are adopting Veeva
Vault RIM
to manage their end-to-end regulatory submission
processes. Recently, Veeva passed the 100th customer
milestone for Veeva Vault RIM, doubling its total number of customers
over the past year.

With its new submission content planning capability now available, Veeva
is bringing together content planning and authoring in a single cloud
application to eliminate the need for multiple systems and manual
tracking that are inherent in today’s submission development process.
Now customers can specify the necessary content, track document status,
and gain full visibility into the progress toward completion – all in
Veeva Vault Submissions.

“Adding submission content planning in Vault Submissions is another
example of Veeva’s continued innovation in regulatory,” said Michael
Martelli, senior manager of Regulatory Operations at Seres Therapeutics.
“The ability to plan, author, and track status in a single application
will drive greater efficiency and speed in the submission process.”

“There is a major transformation underway in life sciences to unify
regulatory information management on one platform,” said John Lawrie,
vice president of Veeva Vault RIM. “Customers are standardizing on Veeva
Vault RIM because they want a global authoritative source for all
regulatory content and product registration data.”

Veeva Vault Submissions is part of the Vault RIM suite of applications
that provide fully integrated RIM capabilities on a single cloud
platform, including product registration management with fully embedded
IDMP capabilities, health authority correspondence and commitment
management, and submission document management, publishing, and archival.

In other news today, Veeva announced that Regeneron Pharmaceuticals
(NASDAQ:REGN) is standardizing on Veeva Vault Submissions and Veeva
Vault eTMF
to further streamline content in clinical and regulatory
operations. Read today’s press
release
to learn how Regeneron is speeding product development,
increasing collaboration, and improving compliance.

To see how Veeva’s new submission content planning capability will
streamline submission development, join the DIA innovation theater
session, “Unified RIM: End-to-end Submission Development – from Planning
Through Archival,” on Tuesday, June 20, at 3:25 p.m. in the exhibit
hall, theater #1 at the DIA 2017 Annual Meeting.

Additional Information

For more information on Veeva Vault RIM, visit: veeva.com/RIM

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veevasystems on Twitter: twitter.com/veevasystems

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 525 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.


Contacts

Veeva Systems
Roger Villareal, 925-264-8885
roger.villareal@veeva.com
or
Lisa
Barbadora, 610-420-3413
pr@veeva.com